Antibiotice S.A. reports lower revenues in 2025 but stronger exports and continued production investments

Romanian pharmaceutical producer Antibiotice S.A. recorded revenues of RON 645.28 million in 2025, down by RON 29.7 million compared to 2024 (RON 675 million), according to the preliminary report submitted to the Bucharest Stock Exchange. Approximately 68% of the decline was driven by reduced sales in the US market, 13% by lower consumption of oral antibiotics, and 4% by contraction in plant-based dietary supplements following the implementation of Law 81/2022.

Total revenues reached RON 687.26 million, down 1% year-on-year, while gross profit stood at RON 60.1 million, in line with the five-year average.

Read also: MedLife surpasses €630 million pro-forma revenue in 2025

Export growth and strong domestic positioning

On the domestic market, the company posted a 2.2% increase in volume, reaching 24.2 million boxes, remaining the only top-10 generics producer to maintain consumption growth. Antibiotice holds a 13.4% value share in injectable anti-infectives and hospital medicines.

The company leads the Romanian market in ointments (19.8%), suppositories and ovules (32.6%), and injectable powders (59.9%), as well as in antifungal active substances based on Nystatin. Globally, Antibiotice is cited as a leader in in-house produced active substances, with an estimated 50% market share.

International sales reached RON 266.26 million, up 7.6%, representing about 40% of total turnover. Finished product exports increased by 10%, with approximately 40% growth in markets such as the UK, Nordic countries, the Netherlands, Hungary, Serbia and Moldova. The company’s products are present in 40 territories worldwide.

In 2025, Antibiotice launched 14 new products, while 93 medicines are undergoing authorization. The company continued investments in sterile and topical production expansion and operationalized its second photovoltaic plant, reaching 3.7 MW installed capacity. It also signed a €75 million financing contract for the “Inova a+” research and production center for critical medicines.

Photo: antibiotice.ro